Swiss National Bank Has $5.30 Million Holdings in Vericel Co. (NASDAQ:VCEL)

Swiss National Bank grew its position in shares of Vericel Co. (NASDAQ:VCEL) by 6.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 96,500 shares of the biotechnology company’s stock after buying an additional 6,100 shares during the quarter. Swiss National Bank owned approximately 0.20% of Vericel worth $5,299,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Arcadia Investment Management Corp MI bought a new position in Vericel during the fourth quarter valued at approximately $48,000. Smartleaf Asset Management LLC increased its stake in shares of Vericel by 511.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 1,058 shares during the last quarter. Geneos Wealth Management Inc. raised its holdings in shares of Vericel by 826.6% during the 4th quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company’s stock valued at $138,000 after purchasing an additional 2,240 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Vericel in the 3rd quarter valued at $146,000. Finally, KBC Group NV boosted its holdings in Vericel by 82.5% in the fourth quarter. KBC Group NV now owns 2,707 shares of the biotechnology company’s stock worth $149,000 after purchasing an additional 1,224 shares in the last quarter.

Insider Buying and Selling

In other news, insider Jonathan Siegal sold 3,908 shares of Vericel stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $61.99, for a total transaction of $242,256.92. Following the sale, the insider now directly owns 1,206 shares in the company, valued at approximately $74,759.94. The trade was a 76.42 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Dominick Colangelo sold 26,592 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $45.78, for a total transaction of $1,217,381.76. Following the completion of the transaction, the chief executive officer now directly owns 259,997 shares of the company’s stock, valued at $11,902,662.66. This trade represents a 9.28 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 34,092 shares of company stock valued at $1,683,582 over the last three months. 5.20% of the stock is owned by corporate insiders.

Analyst Ratings Changes

VCEL has been the topic of several recent research reports. BTIG Research raised their target price on Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Truist Financial reissued a “buy” rating and issued a $61.00 price objective (down from $67.00) on shares of Vericel in a research note on Monday, March 3rd. Stephens reiterated an “overweight” rating and set a $65.00 price target on shares of Vericel in a report on Wednesday, January 15th. HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of Vericel in a research note on Friday, February 28th. Finally, StockNews.com upgraded shares of Vericel from a “sell” rating to a “hold” rating in a research note on Saturday, March 8th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $62.29.

Vericel Price Performance

NASDAQ:VCEL opened at $47.94 on Tuesday. The stock has a market cap of $2.40 billion, a P/E ratio of 799.13 and a beta of 1.78. The company has a fifty day moving average price of $54.16 and a 200 day moving average price of $51.73. Vericel Co. has a one year low of $39.12 and a one year high of $63.00.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.